Comparison of the <i>in vivo</i> efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against <i>Pseudomonas aeruginosa in</i> 72-hour murine thigh infection model
Despite susceptibility to both cefiderocol and ceftolozane/tazobactam, cefiderocol provided a more rapid kill profile and achieved a greater magnitude of bactericidal activity relative to ceftolozane/tazobactam. While frank resistance did not develop to either compound, differences in the rate and extent of kill were observed.
Authors
- Samantha Nicolau
- Christian M Gill (ORCID: https://orcid.org/0000-0003-3606-0761)
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Pranita D. Tamma (ORCID: https://orcid.org/0000-0002-4143-6324)
- Patricia J. Simner (ORCID: https://orcid.org/0000-0001-6134-151X)
Institutions
- Hartford Hospital (US)
- Johns Hopkins University (US)
- Institut Pasteur (FR)
- Johns Hopkins Medicine (US)
- Sanofi (United States) (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1080/23744235.2025.2471822
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59